Fundraising Fox
/Companies
Sign in

Myosana Therapeutics

Seattle, US · Founded 2018 · Delaware corporation · 5 known investors

Find your way into Myosana Therapeutics

Each arrow is one introduction. Sign up to fill in the first one.

174 people can intro you to Nick

Ask Swetha Murali to introduce you to Nick Whitehead

You →Swetha · together at University of Sydney →Nick

88 people can intro you to Stan

Ask Jamie Chen to introduce you to Stan Froehner

You →Jamie · together at UW Medicine →Stan

Sign up to find every way you can get introduced to Myosana Therapeutics

  • Your email: who you already know at Myosana Therapeutics, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Myosana Therapeutics team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Myosana Therapeutics develops non-viral, muscle-targeted gene therapies aimed at slowing skeletal muscle degeneration and heart failure in Duchenne muscular dystrophy (DMD) and other neuromuscular and cardiac diseases. The company works in the biotech and gene therapy field.

BiotechDeep TechHealthtechLongevity

Founders & leadership

Myosana Therapeutics was founded in 2018 by Stan Froehner and Nick Whitehead.

SFStan Froehner
Stan FroehnerCFO, Chairman, and Co-FounderStan Froehner is CFO, Chairman, and Co-Founder of Myosana Therapeutics, a biotech company developing non-viral gene therapies targeting skeletal and cardiac muscle degeneration in neuromuscular diseases including Duchenne muscular dystrophy.
NWNick Whitehead
Nick WhiteheadCEO, CSO & Co-FounderNick Whitehead is co-founder and CSO of Myosana Therapeutics, which develops non-viral gene therapies for neuromuscular and cardiac diseases. He has more than 20 years of expertise in muscle physiology and DMD research.
MLMatthew Lumley
Matthew LumleyAdvisor
DM
Debra MillerNamed on SEC filing

Investors · 5

Also in the syndicate · 5

CureDuchenne VenturesMDAMuscular Dystrophy AssociationParent Project Muscular DystrophyPPMD

Reported raises · per SEC filings

Form D private placements

$6.4M disclosed across 1 round · 2022

▶$6.4MraisedDec 2022 · 6 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Matthew LumleyDirector
  • Stanley C. FroehnerExecutive Officer, Director, Promoter
  • Debra MillerDirector
  • Nicholas P. WhiteheadExecutive Officer, Director, Promoter
Offering amount
$6.4M
Amount sold
$6.4M
First sale
Nov 2022
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 4

Day One BiopharmaceuticalsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.
Sionna TherapeuticsSionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs. It is advancing a portfolio of NBD1 stabilizers and complementary CFTR modulators intended to be used in combination to normalize CFTR function in CF patients.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
MosannaMosanna is a pharmaceutical company developing a non-invasive nasal spray therapy for obstructive sleep apnea (OSA) that reactivates the body's natural airway reflex to keep the upper airway open during sleep. Its lead candidate, MOS-118, is a small molecule delivered before bedtime that stimulates upper airway dilator muscles to reduce apnea and hypopnea episodes.

Companies working in the same space as Myosana Therapeutics.

In the news

Myosana Therapeutics Raises $5 Million in Seed Funding - BioSpacebiospace.com · Jan 2023PPMD Invests $500,000 in Myosana Therapeutics to Advance Non-Viral Gene Therapy Platform - Myosana Therapeuticsmyosanatherapeutics.com · Jan 2023

Frequently asked questions

What does Myosana Therapeutics do?
Myosana Therapeutics develops non-viral, muscle-targeted gene therapies aimed at slowing skeletal muscle degeneration and heart failure in Duchenne muscular dystrophy (DMD) and other neuromuscular and cardiac diseases. The company works in the biotech and gene therapy field.
Who founded Myosana Therapeutics?
Myosana Therapeutics was founded by Stan Froehner, Nick Whitehead in 2018.
How much funding has Myosana Therapeutics raised?
Myosana Therapeutics has disclosed $6.4M raised across 1 round.
Where is Myosana Therapeutics headquartered?
Myosana Therapeutics is headquartered in Seattle, US.